Ala-Glu-Asp-Gly Tetrapeptide (Epitalon)
Soviet Cold War science. Classified until 1991. Telomere claims no Western lab has verified.
Longevity / TelomereNot approved. Reviewed by the FDA Pharmacy Compounding Advisory Committee in July 2026 among seven nominated peptides, with FDA briefing documents proposing it not be added to the 503A bulk drug substances list (advisory input, not a final agency determination).
GLP-1 drug plus add-on metabolism peptides
approved drug plus unproven add-ons
Mixed: approved incretin drug plus experimental peptidesThe GLP-1 base drugs are FDA-approved: semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are cleared for diabetes and/or obesity. GLP-1 means glucagon-like peptide-1, a gut hormone that signals fullness; tirzepatide also hits a second receptor called GIP. The add-on peptides are NOT approved as weight drugs: AOD-9604 has no drug approval (it holds a narrow food-ingredient GRAS notice and the FDA declined to add it to the compounding list in December 2024), and MOTS-c and 5-Amino-1MQ are sold as research chemicals only. The stack as a whole is not an approved regimen.
FDA-approved GHRH drug used off-label in a fat-loss stack
approved drug, off-label stack
Growth-hormone-releasing peptide stackTesamorelin is FDA-approved, but ONLY as Egrifta/Egrifta SV to reduce excess belly fat in people with HIV-associated lipodystrophy. Using it for general fat loss or anti-aging is off-label. Ipamorelin is not FDA-approved for anything, and the combination is not approved.
GHRH Analog + GH Secretagogue Stack
The most commercially active unapproved stack, and the most formally flagged by the FDA.
GH SecretagogueUnapproved; both reviewed by PCAC and recommended against 503A bulks inclusion
Triple-stack adding an older, stronger secretagogue
aggressive GH triple-stack
Growth-hormone-releasing peptide stackNo component is FDA-approved for any use. GHRP-2 and GHRP-6 are also on the FDA's list of peptides that cannot be legally compounded. Available only through unregulated channels.
GHK-Cu + BPC-157 + TB-500 skin-and-healing blend
Cosmetic and healing blend
Informal multi-peptide blend (copper tripeptide plus two repair peptides)None of the three ingredients is an FDA-approved drug. In late 2023 the FDA put BPC-157 and TB-500 on a restricted list (Category 2) that blocks pharmacies from compounding them. Most product sold is labeled research-use-only, not for human use.
GLOW blend plus KPV anti-inflammatory tripeptide
Skin, healing, and anti-inflammation blend
Informal multi-peptide blend (GLOW plus an anti-inflammatory tripeptide)No ingredient in KLOW is an FDA-approved drug. BPC-157 and TB-500 were placed on the FDA restricted compounding list in late 2023. KPV and GHK-Cu are not approved drugs either. Almost all product is sold as research-use-only, not for human use.
Russian nootropic and anti-anxiety peptide pair
russian nootropic pair
Synthetic regulatory peptides (ACTH-fragment analog + tuftsin analog), used intranasallyThe US Food and Drug Administration has not approved Semax or Selank for any use. They are not recognized US medicines. They are registered medicines in Russia.
Older once-approved GHRH analog used in milder GH stacks
once-approved, now compounded
Growth-hormone-releasing peptide stackSermorelin was FDA-approved in 1997 as Geref, but only as a diagnostic for childhood growth-hormone deficiency, not for anti-aging or fat loss; the brand was voluntarily discontinued in 2008 for business reasons. Today's sermorelin is sold as a compounded product off-label; Ipamorelin is not approved.
BPC-157 + TB-500 + GHK-Cu broader-healing trio
broad healing
peptide combination (injectable + copper peptide)Not FDA-approved as a stack. BPC-157 and TB-500 are unapproved drugs; BPC-157 was placed in compounding Category 2 in 2023-2024. GHK-Cu is permitted in topical cosmetics, but injectable GHK-Cu is not an approved drug and falls under the same compounding scrutiny.
BPC-157 + TB-500 injury-recovery peptide pairing
injury recovery
injectable peptide combination (research chemical)Not FDA-approved for any use. Neither peptide is an approved drug. The FDA placed BPC-157 in Category 2 of the 503A compounding bulk-substances list in 2023-2024, citing safety concerns and lack of human data; an April 2026 HHS announcement signaled intent to remove it from Category 2, but that process was not finalized at the time of writing.